Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

NCT00055562 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
274
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Celgene Corporation